Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR

At Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR in Berlin, the clinical trial portfolio is focused entirely on respiratory tract diseases, especially asthma and chronic obstructive pulmonary disease. The studies are designed to evaluate new and existing treatment options, with a strong emphasis on better control of symptoms, fewer flare-ups, and improved lung function.

• Research in asthma includes studies for adults with uncontrolled, severe, mild, and moderate disease, aiming to test therapies that may reduce exacerbations and improve day-to-day breathing control.
• COPD trials examine moderate to very severe disease, chronic bronchitis, and exacerbation-prone patients, with the goal of assessing treatments that may lower worsening episodes and support long-term management.
• Several studies focus on inhaled and biologic approaches, including comparisons of treatment effectiveness and safety in people who remain symptomatic despite standard care.

Overall, the site is contributing to research on airway inflammation, exacerbation prevention, and practical treatment improvements for common chronic lung conditions.

A major part of the research at this site centers on asthma, including inadequately controlled asthma, severe asthma, and mild to moderate asthma. These trials are exploring whether new inhaled therapies and other add-on treatments can improve breathing tests, reduce rescue medication use, and prevent severe attacks.

• Studies are assessing new options for people whose asthma is not well controlled with standard inhaled therapy.
• Research also looks at whether add-on treatments can reduce asthma exacerbations and improve overall disease control.
• Some trials compare different inhaler formulations to determine whether they offer similar or better lung function outcomes.

This work is aimed at finding safer and more effective ways to manage persistent airway disease in people living with ongoing symptoms.

The site also conducts important studies in chronic obstructive pulmonary disease, including COPD with chronic bronchitis and more advanced forms of the disease. The main purpose of these trials is to evaluate therapies that may reduce worsening episodes, improve symptom control, and support better daily breathing.

• COPD research includes patients with moderate to very severe disease, reflecting a focus on more challenging cases that need improved treatment options.
• Several trials examine whether new medicines can lower the rate of COPD exacerbations and help patients stay stable for longer.
• Some studies compare active treatments with placebo or standard care to understand treatment effectiveness in real-world disease management.

This portfolio highlights ongoing efforts to advance care for people with chronic airflow limitation and frequent disease flare-ups.

Beyond disease-specific care, the clinical trials at this Berlin research site include studies that test the safety, tolerability, and performance of emerging therapies for asthma and COPD. The research is aimed at understanding how new treatments compare with existing options and whether they can offer meaningful benefits for patients.

• Trials are evaluating newer biologic and inhaled therapies to see whether they can better control respiratory symptoms and reduce the risk of flare-ups.
• Comparative studies are helping determine whether different treatment formulations provide similar or improved clinical effectiveness.
• Some research also examines safety, tolerability, and how the body responds to investigational treatments over time.

This makes the site a active contributor to research on modern respiratory medicine and the development of more tailored treatment strategies.